ArticleAndrology2026
Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours.
Article in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTesticular germ cell tumours (TGCTs) are amongst the most common malignancies in young men, and their incidence is increasing worldwide. Tissue heterogeneity hampers efforts to understand how TGCT precursors (termed germ cell neoplasia in situ; GCNIS) emerge and progress, restricting elucidation of new strategies for diagnosis and management.
objectivesThis study reports the use of spatial transcriptomic analysis in TGCT tissue sections. MATERIALS AND
methodsOver 90 regions of interest (ROIs) were identified in sections from four TGCT patients' samples, three with non-seminoma, one seminoma. Transcripts in each ROI were sequenced and examined using the NanoString GeoMx spatial whole transcriptomics workflow, the values normalised and analysed using Degust RNA-Seq and Ingenuity Pathway Analysis software.
resultsThe distribution and expression of functional markers in specific cell types was used to map individual tumours, GCNIS, and tumour-adjacent regions. Significant heterogeneity in TGCTs and surrounding areas is documented between patients and across different regions in the same tumour. Immune cell-related transcripts encoding macrophage, T cell, B cell, natural killer cell, dendritic cells and neutrophil subsets were identified as contributing substantially to tumour heterogeneity. Assessment of ROIs containing GCNIS and areas immediately adjacent from two individual non-seminoma tumour samples identified the TGFβ family as contributing to upstream regulation of transcripts in both patients; known activin A target genes were differentially expressed between the GCNIS and microenvironment ROIs. In addition, two discrete tumour areas within the seminoma sample displayed distinct transcript profiles, one featuring higher levels of immune cell-related transcripts, and the other TGFβ superfamily transcripts.
conclusionThese findings highlight aspects of the complex challenge faced while seeking therapeutic targets to enable tumour spread restriction. However, these outcomes reinforce knowledge that TGFβ family members can influence seminoma fate and provide new evidence of their potential contribution to the transition of GCNIS cells into tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.